Regeneron Hypes New Eczema Drug Dupixent In 1Q
Executive Summary
Analysts have significantly upped their 2017 sales forecasts for Regeneron and Sanofi's recently launched eczema drug Dupixent on the back of a strong first few weeks on the market and positive vibes from Regeneron – which held a spotlight firmly on its new therapy during its May 4 first quarter earnings call.
You may also be interested in...
Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.